01—Abstract
Summary
Summary of the 10-Q filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Beigene, Ltd. (ONC) reported a significant increase in total revenues for the second quarter of 2024, reaching $929.2 milliona, a 56% rise compared to the same period last year.
This growth was primarily driven by a substantial 107% increase in BRUKINSA sales, totaling $637.4 millionb globally, with particularly strong performance in the U.S. and Europe. Despite the revenue growth, the company reported a GAAP net loss of $120.4 million for the quarter. The company also highlighted its strategic advancements, including the opening of its new U.S. facility in Hopewell, New Jersey, and progress in its pivotal programs for sonrotoclax and BGB-16673.
While the company's operating loss narrowed significantly, it continues to invest heavily in research and development and selling, general, and administrative expenses to support its product pipeline and commercialization efforts. Investors should note the significant decline in collaboration revenue due to the termination of prior agreements, which is more than offset by the robust growth in product revenue.
The company's cash position remains strong at $2.6 billionc, though it is managing a substantial amount of debt, with over $851 million due within the next 12 months. Beigene appears to be on a positive trajectory with its key product, BRUKINSA, gaining market share and driving substantial revenue growth, but continued investment in R&D and commercial expansion will be crucial for future profitability.
02—Key points
Key Highlights
- Total revenues increased by 56% year-over-year to $929.2 million in Q2 2024.
- BRUKINSA global sales grew by 107% year-over-year to $637.4 million in Q2 2024.
- U.S. BRUKINSA sales grew by 114.4% year-over-year to $479.4 million in Q2 2024.
- GAAP net loss for the quarter was $120.4 million, a significant improvement from $381.1 million in Q2 2023.
- GAAP loss from operations narrowed to $107.2 million, an improvement from $318.7 million in Q2 2023.
- Collaboration revenue decreased by 81% year-over-year to $8.0 million.
- The company opened its flagship U.S. facility in Hopewell, New Jersey.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2024, BeOne Medicines Ltd. lost $0.13.
- Revenue$929.2M100.0%
- Cost of revenue−$138.1M14.9%
- Gross profit$791.0M85.1%
- Operating costs−$898.2M96.7%
- Operating income−$107.2M11.5%
- Interest, other & tax−$13.2M1.4%
- Net income−$120.4M13.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 7, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $929.17M$595.26M | +56.1% |
| Gross Profit | $791.03M$499.27M | +58.4% |
| R&D Expenses | $454.47M$422.76M | +7.5% |
| SG&A Expenses | $443.73M$395.03M | +12.3% |
| Operating Expenses | $898.20M$817.99M | +9.8% |
| Operating Income | -$107.16M-$318.71M | +66.4% |
| Interest Expense | $13.23M$4.89M | +170.6% |
| Net Income | -$120.41M-$381.14M | +68.4% |
| EPS (Basic) | $-0.09$-0.28 | +67.9% |
| EPS (Diluted) | $-0.09$-0.28 | +67.9% |
| Shares Outstanding (Basic) | 1.36B1.36B | +0.1% |
| Shares Outstanding (Diluted) | 1.36B1.36B | +0.1% |
05—Questions
Frequently Asked Questions
What is the main driver of Beigene's revenue growth in this quarter?
The primary driver of Beigene's revenue growth in the second quarter of 2024 is the significant increase in sales of its internally developed oncology medicine, BRUKINSA. Global sales of BRUKINSA increased by 107% year-over-year, reaching $637.4 million, propelled by strong performance in key markets like the U.S. and Europe.
What is the company's current financial health and outlook?
Beigene ended the quarter with $2.6 billion in cash, cash equivalents, and restricted cash, providing a solid liquidity position. While the company continues to incur net losses ($120.4 million in Q2 2024), this represents a substantial improvement compared to the prior year's quarter. The company expects its existing cash to fund operations for at least the next 12 months, but it also has significant short-term debt obligations totaling over $851 million due within the next year, which it anticipates refinancing.
How did the company's R&D and SG&A expenses change compared to last year?
Research and Development (R&D) expenses increased by 7.5% to $454.5 million for the three months ended June 30, 2024, compared to the same period in 2023, driven by increased Amgen co-development expenses and development milestone fees. Selling, General, and Administrative (SG&A) expenses also increased by 12.3% to $443.7 million, primarily due to investments in expanding commercial activities to support product launches. Despite these increases, SG&A expenses as a percentage of product sales decreased significantly, indicating improved operational leverage.
06—Continue